Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Patent metadata

Field	Value
Publication number	US-2020399718-A1
Application number	US-202016892132-A
Country	US
Kind code	A1
Filing date	Jun 3, 2020
Priority date	Feb 21, 2002
Publication date	Dec 24, 2020
Grant date	—

Abstract

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

First claim

What is claimed is:

1 . An isolated negative-sense single-stranded RNA virus MPV belonging to the sub-family Pneumovirinae of the family Paramyxoviridae and identifiable as phylogenetically corresponding to the genus Metapneumovirus , wherein the virus is phylogenetically more closely related to a virus isolate comprising the nucleotide sequence of SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, or SEQ ID NO:21 than it is related to turkey rhinotracheitis virus, the etiological agent of avian rhinotracheitis.

2 . A kit for determining the presence of metapneumovirus (MPV) in a mammalian subject, the kit comprising:
a DNA probe of at least 10 nucleotides that specifically hybridizes to a target polynucleotide, wherein the DNA probe does not specifically hybridize to a polynucleotide from avian pneumovirus (APV); wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:374 and 376 or the complement of the sequence; wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA; and wherein the target polynucleotide comprises a first nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:375 or the complement of the first nucleic acid; or wherein the target polynucleotide comprises a second nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:377 or the complement of the second nucleic acid.

3 . The kit of claim 2 , wherein the DNA probe comprises at least 25 nucleotides.

4 . The kit of claim 2 , wherein the DNA probe comprises at least 40 nucleotides.

5 . The kit of claim 2 , wherein the DNA probe further comprises a detectable marker.

6 . The kit of claim 2 , wherein the target polynucleotide comprises a nucleic acid encoding SEQ ID NO:375 or wherein the target polynucleotide comprises a nucleic acid encoding SEQ ID NO:377.

7 . A method for detecting metapneumovirus (MPV) subtype A2 or B2 in a mammalian subject, the method comprising:
contacting a sample from the subject with a probe nucleic acid of at least 10 nucleotides that hybridizes under stringent conditions to a sequence encoding a polypeptide that is at least 90% identical to one of SEQ ID NOs:375 and 377 or the complement of the sequence; and detecting hybridization of the probe and the target polynucleotide; wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:374 and 376 or the complement of the sequence; and wherein the stringent conditions include a hybridization buffer comprising 6×SSC and 1 mM EDTA.

8 . The method according to claim 7 , wherein the probe nucleic acid comprises at least 25 nucleotides.

9 . The method according to claim 7 , wherein the probe nucleic acid comprises at least 40 nucleotides.

10 . The method according to claim 7 , wherein detecting hybridization of the probe and the target polynucleotide comprises performing PCR with the probe nucleic acid as a primer.

11 . The method according to claim 7 , wherein the mammalian subject is a human.

12 . The method according to claim 7 , wherein the probe nucleic acid comprises a detectable marker.

13 . The method according to claim 7 , wherein the probe is attached to a solid support.

14 . The method according to claim 7 , wherein the target polynucleotide comprises a nucleic acid encoding one of SEQ ID NOs: 375 and 377.

15 . The method according to claim 7 , wherein the target polynucleotide comprises the complement of a nucleic acid encoding one of SEQ ID NOs: 375 and 377.

Assignees

• Univ Erasmus Med Ct Rotterdam

Inventors

• Fouchier Ronaldus Adrianus Maria
• Van Den Hoogen Bernadetta Gerarda
• Osterhaus Albertus Dominicus Marcellinus Erasmus
• De Jong Jan Cornelius
• Groen Jan

Classifications

• C07K16/11

  Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV] · CPC title

• A61K39/155

  Paramyxoviridae, e.g. parainfluenza virus · CPC title

• C12N7/00 Primary

  Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title